Contribution of annexin A1 to anticancer immunosurveillance

Contribution of annexin A1 to anticancer immunosurveillance

Mouse cancers lacking the expression of annexin A1 (ANXA1) fail to respond to immunogenic chemotherapies. This has been initially explained by the requirement of extracellular ANXA1 (which is released from dying cancer cells) to engage formyl peptide receptor-1 (FPR1) on dendritic cells (DC) for the...

Full description

Bibliographic Details
Main Authors: Elisa Elena Baracco, Gautier Stoll, Peter Van Endert, Laurence Zitvogel, Erika Vacchelli, Guido Kroemer
Format: Article
Language:English
Published: Taylor & Francis Group 2019-11-01
Series:OncoImmunology
Subjects:
calreticulin
chemotherapy
immunogenic cell death
immunotherapy
tumor immune infiltrate
prognostic markers
Online Access:http://dx.doi.org/10.1080/2162402X.2019.1647760

Internet

http://dx.doi.org/10.1080/2162402X.2019.1647760

Similar Items